Michael Burkes Brophy Sells 495 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 495 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $141.28, for a total value of $69,933.60. Following the completion of the transaction, the chief financial officer owned 71,249 shares in the company, valued at $10,066,058.72. This represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $139.50, for a total value of $105,322.50.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $83,852.58.
• On Monday, April 28th, Michael Burkes Brophy sold 2,018 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $307,099.24.

Natera Stock Performance

Shares of Natera stock traded up $3.25 on Thursday, hitting $141.07. The company's stock had a trading volume of 1,421,449 shares, compared to its average volume of 1,212,550. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm has a fifty day moving average price of $159.24 and a 200-day moving average price of $157.55. The company has a market capitalization of $19.26 billion, a price-to-earnings ratio of -95.97 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same period in the prior year, the firm posted ($0.56) earnings per share. The firm's quarterly revenue was up 36.5% on a year-over-year basis. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Callan Family Office LLC purchased a new stake in Natera in the 2nd quarter valued at approximately $610,000. Vontobel Holding Ltd. boosted its holdings in Natera by 58.3% in the 2nd quarter. Vontobel Holding Ltd. now owns 2,917 shares of the medical research company's stock valued at $493,000 after purchasing an additional 1,074 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in Natera by 17.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 6,311 shares of the medical research company's stock valued at $1,066,000 after purchasing an additional 959 shares in the last quarter. Narwhal Capital Management boosted its holdings in Natera by 33.3% in the 2nd quarter. Narwhal Capital Management now owns 13,325 shares of the medical research company's stock valued at $2,251,000 after purchasing an additional 3,332 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in Natera by 1.8% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 44,400 shares of the medical research company's stock valued at $7,501,000 after purchasing an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NTRA. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Barclays increased their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Finally, Piper Sandler increased their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.